Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 8/20 | 0.61 |
| ▸ | RXRA | P19793 | 7/20 | 0.61 |
| ▸ | RXRG | P48443 | 7/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312525 | 0.94 | RXRA (0.59) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL13312522 | 0.92 | RXRA (0.55) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL13312520 | 0.90 | RXRA (0.55) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL13312531 | 0.90 | RXRA (0.55) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL13312527 | 0.90 | RXRA (0.55) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL13312516 | 0.90 | RXRA (0.55) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL13312426 | 0.90 | RXRA (0.55) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL3500903 | 0.90 | RXRA (0.49) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL13312544 | 0.90 | RXRA (0.54) | RXRBRXRARXRGPTGER4PTGER2 | |
| SCHEMBL3502821 | 0.89 | RXRA (0.53) | RXRBRXRARXRGPTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | RXRB 465/4885RXRA 475/4885RXRG 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.